4-methylumbilliferon (4-MU) as a Potential Treatment Against Cerebral ischemia and Reperfusion Injury in Rats; An Experimental Study.

Introduction: Ischemic stroke (IS) is one of the three main fatal disorders and is a major health challenge. 4- methylumbelliferone (4-MU) is one of the coumarin derivatives (7–hydroxy-4–methylcoumarin) with antioxidant and anti-inflammatory impact. This study was conducted to elucidate the neuropro...

Descripción completa

Detalles Bibliográficos
Publicado en:Archives of Academic Emergency Medicine Vol. 13; no. 1; pp. 1 - 11
Autores principales: Mirshekari Jahangiri, Hamzeh, Moradi, Alireza, Nazarinia, Donya, Aboutaleb, Nahid
Formato: pictorial research tables/charts Journal Article
Publicado: Shahid Beheshti University of Medical Sciences 2025
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=190500665&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 190500665
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        26454904
        MFMK
      jtl: Archives of Academic Emergency Medicine
      issn: 26454904
      maglogo: N
    pubinfo:
      dt: 2025
      vid: 13
      iid: 1
      pid: 87963
      pub: Shahid Beheshti University of Medical Sciences
    artinfo:
      ui:
        190500665
        190500665
        190500665
        10.22037/aaem.v13i1.2456
        190500665
      ppf: 1
      ppct: 10
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: 4-methylumbilliferon (4-MU) as a Potential Treatment Against Cerebral ischemia and Reperfusion Injury in Rats; An Experimental Study.
      aug:
        au:
          Mirshekari Jahangiri, Hamzeh
          Moradi, Alireza
          Nazarinia, Donya
          Aboutaleb, Nahid
        affil: Physiology Research Center, Iran University of Medical Sciences, Tehran, Iran.
      sug:
        subj:
          Cerebral Ischemia Drug Therapy
          Reperfusion Injury Drug Therapy
          Benzopyrans Analogs and Derivatives
          Neuroprotective Agents Therapeutic Use
          Antiinflammatory Agents Therapeutic Use
          Treatment Outcomes Evaluation
          Animal Studies
          Rats
          Experimental Studies
          Funding Source
          Gastrointestinal Agents
          Neuroprotective Agents Administration and Dosage
          Staining and Labeling
          Blotting, Western
          Interleukins
          Intercellular Signaling Peptides and Proteins
          Caspases
          Gene Expression
          Random Assignment
          Descriptive Statistics
          Post Hoc Analysis
          Data Analysis Software
      ab: Introduction: Ischemic stroke (IS) is one of the three main fatal disorders and is a major health challenge. 4- methylumbelliferone (4-MU) is one of the coumarin derivatives (7–hydroxy-4–methylcoumarin) with antioxidant and anti-inflammatory impact. This study was conducted to elucidate the neuroprotective effects and anti-inflammatory impact of 4-MU in a rodent model of IS. Methods: The IS model was induced by middle cerebral artery occlusion (MCAO) for 1 hour and reperfusion was established for 24 hours. 44 Male Wistar rats were divided into four groups: 1) Sham, 2) MCAO, 3) MCAO + Vehicle, and 4) MCAO + 4-MU (25 mg/kg). Evaluation of neurological deficit was performed using Garcia’s score. 2,3,5-triphenoyl-2H-tetrazolium chloride (TTC) staining was employed to measure infarct size. Nissl staining was applied to determine neuronal loss. Moreover, western blotting was utilized to detect the expression of the proteins relevant to the TLR4/NF-KB/NLRP3 axis (p–NF–KB p65, TLR4, NLRP3, IL-1β, IL-10, IL-18, ASC, and Caspase-1). Results: It was observed that MCAO caused neurological deficit (P<0.0001), infarct (P<0.0001), and neuronal loss (P<0.002); up-regulated NLRP3 (P<0.0001), TLR4 (P<0.0001), p–NF–KB p65 (P<0.0005), IL-1β (P<0.0014), IL-18 (P<0.0001), ASC (P<0.0027), and Caspase-1 (P<0.0052); and reduced IL-10 concentrations (P<0.0024). Administration of 4-MU (25 mg/kg) quickly after reperfusion reduced neurological deficit (P<0.0001), infarct size (P<0.0001), neuronal loss (P<0.0058), and down-regulated NLRP3 (P<0.0257), TLR4 (P<0.0001), p–NF–KB p65 (P<0.0075), IL-1β (P<0.0106), IL-18 (P<0.0005), ASC (P<0.0072), and Caspase-1 (P<0.0315), and increased IL-10 concentrations (P<0.0215). Conclusions: These results indicate that 4-MU can attenuate injury after MCAO by suppressing the TLR4/NF-KB/NLRP3 axis. Our findings show that 4-MU can be considered a novel therapeutic compound to cure IS.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N